• First-in-human ischemic ventricular tachycardia (VT) ablation performed entirely under real-time MRI guidance
• Successful transseptal crossing, left ventricular mapping, and substrate-guided ablation in patient with ICD
• Milestone achievement for Imricor's VISABL-VT clinical trial and the field of MRI-guided electrophysiology

Imricor Medical Systems, Inc. (ASX: IMR), together with Amsterdam University Medical Centre (Amsterdam UMC), has announced the successful completion of the world's first ischemic ventricular tachycardia (VT) ablation performed entirely under real-time MRI guidance in an iCMR lab. The procedure involved several world firsts, including the first-in-human MRI-guided transseptal crossing, first left ventricular mapping and ablation with Imricor's Vision-MR® Ablation Catheter 2.0, and the first substrate (scar)-guided ablation performed under real-time MRI guidance. Importantly, the procedure was also the first to demonstrate the ability to safely and effectively treat high-risk patients with an implantable cardioverter defibrillator (ICD) in the iCMR lab. The successful completion of this landmark procedure marks a critical step forward for Imricor's VISABL-VT clinical trial and a watershed moment for the field of MRI-guided electrophysiology. The achievement reflects the culmination of years of collaborative innovation between Imricor and the world-class clinical team at Amsterdam UMC. This milestone paves the way for broader clinical use of MRI-guided ablations, with additional sites in Europe expected to join the VISABL-VT trial in the coming months.

The ability to perform complex ablations, like ischemic VT, entirely under real-time MRI guidance has been the most requested advancement from the global electrophysiology community. Imricor expects the news of this world-first procedure to drive significant growth in demand and shorten conversion timelines across its customer base as more centers progress towards performing MRI-guided ablations.